Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 10, 2026Discover OncologyOpen Access

Durable response to trametinib in a neurofibromatosis type 1 associated adult glioma—a case report

View Full Paper
Ask AI
Bookmark
Share

Authors

SCSantiago Cabezas-CamareroHospital Clínico San CarlosRPRebeca Pérez-AlfayateHospital Clínico San CarlosCPCarmen PoliduraHospital Clínico San Carlos

Discussion

Loading...

Member takes

Implication

Case report shows trametinib improves glioma outcomes in NF1, suggesting potential therapeutic benefits.

Key Points

  • This report aims to explore the effects of trametinib in treating high-grade gliomas in NF1 patients, particularly in adults.
  • Administered trametinib 2 mg daily to a 49-year-old NF1 patient with a high-grade midline glioma.
  • No tumor biopsy was performed due to high morbidity risks.
  • Observed radiological and neurological changes over an 8-month period.
  • Patient experienced rapid and sustained improvement in radiological and neurological status.
  • Progression of disease occurred after 8 months of treatment with trametinib.

Cite This Study

Cabezas-Camarero et al. (2026) studied this question.

synapsesocial.com/papers/6a508b536eeac72a437a0044https://doi.org/10.1007/s12672-026-05540-w
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cerebrospinal fluid ctDNA as a diagnostic and prognostic tool in gliomas: a systematic review and meta-analysis2025 · 15 citations
  2. 2LTBK-04. LATE BREAKING ABSTRACT: MEK162 (binimetinib) in children with progressive or recurrent low-grade glioma: a multi-institutional phase II and target validation study2022 · 27 citations
  3. 3Druggable genomic landscapes of high-grade gliomas2023 · 16 citations
  4. 4Antiseizure effect of MEK inhibitor in a child with neurofibromatosis type 1—Developmental and epileptic encephalopathy and optic pathway glioma2023 · 9 citations
  5. 5A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 42025 · 21 citations